Quantcast

Latest PTC Therapeutics Inc. Stories

2014-09-17 08:29:28

SOUTH PLAINFIELD, N.J., Sept. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the expansion of its global presence with the addition of key executives to leadership positions in PTC's global commercial team and the establishment of its international headquarters in Dublin, Ireland. Significant pre-launch activities are well underway as PTC prepares for the commercial launch of Translarna(TM) (ataluren) in the European Union. In August of this year,...

2014-09-09 08:31:34

-Top-line data expected H2 2015- SOUTH PLAINFIELD, N.J., Sept. 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has completed enrollment of ACT DMD, the Phase 3 confirmatory trial of Translarna(TM) (ataluren) for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Top-line data from the trial is expected in the second half of 2015 and will support further approvals globally, following European approval received earlier this...

2014-08-20 16:25:31

SOUTH PLAINFIELD, N.J., Aug. 20, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will participate at two upcoming investor conferences: http://photos.prnewswire.com/prnvar/20010919/PTCLOGO - FBR 1(st) Annual Healthcare Conference at the Four Seasons Hotel in Boston on Wednesday, September 3(rd) - Citi's 9(th) Annual Biotech Conference at The Mandarin Oriental Boston on Thursday, September 4(th) In addition, management will present a company...

2014-08-07 16:27:47

-Results published in Science show small molecule SMN2 splicing modifiers to be effective in SMA mouse models- SOUTH PLAINFIELD, N.J., Aug. 7, 2014 /PRNewswire/ -- Today the journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy (SMA). Scientists from Roche Pharma Research and Early Development...

2014-08-01 16:24:12

SOUTH PLAINFIELD, N.J., Aug. 1, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on July 31, 2014 it approved non-statutory stock options to purchase an aggregate of 67,700 shares of its common stock to seven new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO The inducement grants were approved by PTC's...

2014-07-30 08:33:04

SOUTH PLAINFIELD, N.J., July 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Wedbush Life Sciences Management Access Conference on Tuesday, August 12th at 4:15 pm ET at the Le Parker Meridien in New York City. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website...

2014-07-24 16:27:50

SOUTH PLAINFIELD, N.J., July 24, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2014 financial results and provide an update on the company's business and outlook on Thursday, August 7, 2014 at 8:30 a.m. (ET) before the opening of the market. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO The call can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152...

2014-07-09 16:28:13

-French ATU Cohort and Other Named Patient Programs Authorized - SOUTH PLAINFIELD, N.J., July 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna(TM) (ataluren) available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, PTC will make Translarna available to nonsense...

2014-06-30 08:30:32

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein. The Phase 3 confirmatory trial is...

2014-06-30 08:30:29

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it is the recipient of Parent Project Muscular Dystrophy's (PPMD) "Path to Progress" award, honoring PTC's 16 years of commitment to bring the first-ever therapy for the underlying cause of the disorder to patients with Duchenne muscular dystrophy (DMD). The award was presented at PPMD's Annual Connect Conference in Chicago, Illinois....


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'